Biochemistry and molecular biology of Canavan disease

Reuben Matalon, Kimberlee Michals-Matalon

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Canavan in 1931 described spongy degeneration of the brain in a child who was thought to have had Schilder's disease. Since that classic histological description, Canavan disease has become a distinct clinical entity, with the recognition by Van Bogaert and Bertrand that this is an autosomal recessive disease prevalant among children of Jewish extraction. Recent advances in the understanding of the biochemical defect led to an increase in awareness and ease in diagnosis, and indeed the disease is not as rare as initially thought. Exploring the molecular aspects of Canavan disease has led to exciting new developments in carrier detection and prevention of Canavan disease. Work is underway in our laboratory to develop a knock-out mouse for Canavan disease for understanding of the pathophysiology of this disease and formulating gene therapy.

Original languageEnglish (US)
Pages (from-to)507-513
Number of pages7
JournalNeurochemical Research
Volume24
Issue number4
StatePublished - 1999
Externally publishedYes

Fingerprint

Canavan Disease
Biochemistry
Molecular biology
Molecular Biology
Diffuse Cerebral Sclerosis of Schilder
Knockout Mice
Genetic Therapy
Gene therapy
Brain

Keywords

  • Aspartoacylase
  • Canavan disease
  • N-acetylaspartic acid
  • Spongy degeneration of the brain

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry

Cite this

Biochemistry and molecular biology of Canavan disease. / Matalon, Reuben; Michals-Matalon, Kimberlee.

In: Neurochemical Research, Vol. 24, No. 4, 1999, p. 507-513.

Research output: Contribution to journalArticle

Matalon, R & Michals-Matalon, K 1999, 'Biochemistry and molecular biology of Canavan disease', Neurochemical Research, vol. 24, no. 4, pp. 507-513.
Matalon, Reuben ; Michals-Matalon, Kimberlee. / Biochemistry and molecular biology of Canavan disease. In: Neurochemical Research. 1999 ; Vol. 24, No. 4. pp. 507-513.
@article{49b1b0b169fe43c48024ac26179c3c5f,
title = "Biochemistry and molecular biology of Canavan disease",
abstract = "Canavan in 1931 described spongy degeneration of the brain in a child who was thought to have had Schilder's disease. Since that classic histological description, Canavan disease has become a distinct clinical entity, with the recognition by Van Bogaert and Bertrand that this is an autosomal recessive disease prevalant among children of Jewish extraction. Recent advances in the understanding of the biochemical defect led to an increase in awareness and ease in diagnosis, and indeed the disease is not as rare as initially thought. Exploring the molecular aspects of Canavan disease has led to exciting new developments in carrier detection and prevention of Canavan disease. Work is underway in our laboratory to develop a knock-out mouse for Canavan disease for understanding of the pathophysiology of this disease and formulating gene therapy.",
keywords = "Aspartoacylase, Canavan disease, N-acetylaspartic acid, Spongy degeneration of the brain",
author = "Reuben Matalon and Kimberlee Michals-Matalon",
year = "1999",
language = "English (US)",
volume = "24",
pages = "507--513",
journal = "Neurochemical Research",
issn = "0364-3190",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Biochemistry and molecular biology of Canavan disease

AU - Matalon, Reuben

AU - Michals-Matalon, Kimberlee

PY - 1999

Y1 - 1999

N2 - Canavan in 1931 described spongy degeneration of the brain in a child who was thought to have had Schilder's disease. Since that classic histological description, Canavan disease has become a distinct clinical entity, with the recognition by Van Bogaert and Bertrand that this is an autosomal recessive disease prevalant among children of Jewish extraction. Recent advances in the understanding of the biochemical defect led to an increase in awareness and ease in diagnosis, and indeed the disease is not as rare as initially thought. Exploring the molecular aspects of Canavan disease has led to exciting new developments in carrier detection and prevention of Canavan disease. Work is underway in our laboratory to develop a knock-out mouse for Canavan disease for understanding of the pathophysiology of this disease and formulating gene therapy.

AB - Canavan in 1931 described spongy degeneration of the brain in a child who was thought to have had Schilder's disease. Since that classic histological description, Canavan disease has become a distinct clinical entity, with the recognition by Van Bogaert and Bertrand that this is an autosomal recessive disease prevalant among children of Jewish extraction. Recent advances in the understanding of the biochemical defect led to an increase in awareness and ease in diagnosis, and indeed the disease is not as rare as initially thought. Exploring the molecular aspects of Canavan disease has led to exciting new developments in carrier detection and prevention of Canavan disease. Work is underway in our laboratory to develop a knock-out mouse for Canavan disease for understanding of the pathophysiology of this disease and formulating gene therapy.

KW - Aspartoacylase

KW - Canavan disease

KW - N-acetylaspartic acid

KW - Spongy degeneration of the brain

UR - http://www.scopus.com/inward/record.url?scp=0032919537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032919537&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 507

EP - 513

JO - Neurochemical Research

JF - Neurochemical Research

SN - 0364-3190

IS - 4

ER -